63936-02-7

Basic information

• Product Name: 1-isopropyl-1H-1,2,4-triazole
• Synonyms: 1-isopropyl-1H-1,2,4-triazole;1-(1-methylethyl)-1H-1,2,4-Triazole
• CAS NO: 63936-02-7
• Molecular Formula: C₅H₉N₃
• Molecular Weight: 111
• Mol File: 63936-02-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 121-122℃
• Boiling Point: 75-76℃ (12 Torr)
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-isopropyl-1H-1,2,4-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-isopropyl-1H-1,2,4-triazole(63936-02-7)
• EPA Substance Registry System: 1-isopropyl-1H-1,2,4-triazole(63936-02-7)

Safety Data

• Hazardous Substances Data: 63936-02-7(Hazardous Substances Data)

Usage

General Description

1-Isopropyl-1H-1,2,4-triazole is a specialized organic compound, characterized by the fusion of isopropyl and 1,2,4-triazole groups. As an organic triazole, it contains a five-membered ring which consists of two carbon and three nitrogen atoms, making it part of the broader group of heterocyclic compounds. These compounds are notable and extensively used due to their range of applications, which extends from pharmaceuticals to agrochemicals. The specific physical properties and potential uses of 1-isopropyl-1H-1,2,4-triazole can vary considerably and may require detailed scientific analysis in relation to the intended application.

Upstream product

• 70629-60-6 isopropylhydrazine hydrochloride 
• 77287-34-4 formamide 
• 288-88-0 1,2,4-Triazole 
• 75-30-9 2-iodo-propane 

Downstream Products

• 1375075-10-7 2,6-bis{[N-isopropyl-N′-methylene]triazole-2-thione}pyridine 
• 1227958-34-0 2-chloro-1-(2-isopropyl-2H-[1,2,4]triazol-3-yl)ethanone 
• 1401300-81-9 2-(2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)benzenesulfonamide 
• 1282517-74-1 5-[2-(4-bromo-2-fluoro-phenyl)-1H-imidazol-4-yl]-1-isopropyl-1H-[1,2,4]triazole 
• 1282516-06-6 10-(4-chlorophenyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 
• 1282516-01-1 2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-10-phenyl-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 
• 82969-62-8 (2-Chlorphenyl)-(4-fluorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)-(1,2,4-triazol-4-yl)-(3-trifluormethylenphenyl)methan 
• 82969-64-0 (2-Chlorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)-(1,2,4-triazol-1-yl)-(3-trifluormethylphenyl)methan 
• 82969-65-1 (4-Bromphenyl)-(2-chlorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)-(1,2,4-triazol-1-yl)methan 
• 82969-60-6 (2-Chlorphenyl)-(4-fluorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)-(1,2,4-triazol-1-yl)methan 
• 82969-70-8 2-Chlorphenyl-(2-isopropyl-1,2,4-triazol-3-yl)-(3-trifluormethylphenyl)methanol 
• 82969-88-8 5-[Chloro-(2-chloro-phenyl)-(3-trifluoromethyl-phenyl)-methyl]-1-isopropyl-1H-[1,2,4]triazole 
• 82969-68-4 (4-Chlorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)-(3-pyridyl)-(1,2,4-triazol-1-yl)methan 
• 82969-61-7 (2-Chlorphenyl)-(4-fluorphenyl)-(2-isopropyl-1,2,4-triazol-3-yl)pyrazolylmethan 

Relevant articles and documents

Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326

A practical route to PI3K α-selective inhibitor GDC-0326 is reported. The synthesis leverages an existing scheme to a key tetracyclic benzoxazepine intermediate and optimizes it for robustness and scalability, including removing numerous undesired conditions and reagents, as well as eliminating chromatographic purification steps. The process endgame is streamlined to utilize a single-step, stereocontrolled alkylation of the key phenol with a chiral lactamide mesylate, followed by recrystallization of the lactamide ether product, to deliver the desired enantiomer of the active pharmaceutical ingredient (API) GDC-0326.

AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.